Review: azathioprine, infliximab, certolizumab, and adalimumab are effective for maintaining remission in Crohn's disease.
نویسنده
چکیده
Review methods MEDLINE (1966 to May 2007) and Cochrane Library (Issue 2, 2007) were searched for randomized controlled trials (RCTs) or systematic reviews or meta-analyses of RCTs; the Cochrane Inflammatory Bowel Disease Group was contacted. 8 interventions (azathioprine, 5-aminosalicylates, corticosteroids, budesonide, antimycobacterial agents, probiotics, omega-3 fatty acids, and enteral nutrition) were evaluated in systematic reviews, and 6 interventions (methotrexate, infliximab, adalimumab, natalizumab, certolizumab, and cyclosporine) were evaluated in RCTs.
منابع مشابه
Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
BACKGROUND Crohn's disease may be refractory to conventional treatments including corticosteroids and immunosuppressives. Recent studies suggest TNF-alpha blocking agents may be effective in maintaining remission in Crohn's disease. OBJECTIVES To conduct a systematic review of the evidence for the effectiveness of TNF-alpha blocking agents in the maintenance of remission in patients with Croh...
متن کاملTumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysis
INTRODUCTION This meta-analysis compares the effectiveness and safety of tumor necrosis factor α (TNF-α) antibodies (infliximab, adalimumab and certolizumab) with either a placebo or each of them in the treatment of Crohn's disease (CD). MATERIAL AND METHODS A systematic review of literature published up to November 2012 was performed and a meta-analysis of identified studies was carried out....
متن کاملReview article: remission rates achievable by current therapies for inflammatory bowel disease.
BACKGROUND New medical therapies have improved outlook in inflammatory bowel disease but published impact on surgical rates has been modest suggesting that many patients are still not attaining remission. AIM To review remission rates with current medical treatments for inflammatory bowel disease. METHODS We searched MEDLINE (source PUBMED, 1966 to January, 2011). RESULTS Induction and ma...
متن کاملDemyelination in a patient receiving ustekinumab for refractory Crohn's disease.
Ustekinumab is a monoclonal antibody targeting the common part of interleukins 12 and 23, which has proven its efficacy in Crohn's disease1 and not in multiple sclerosis.2 Prevalence of autoimmune diseases including demyelinating disorders is increased in patients with inflammatory bowel disease (IBD)3 and cases of demyelination have been observed in patients receiving TNF-α antagonist. We repo...
متن کاملSystematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease.
BACKGROUND Anti-tumour necrosis factor-alpha agents (anti-TNF) are effective therapies for the treatment of Crohn's disease (CD), but their comparative efficacy is unknown. AIM To perform a network meta-analysis comparing the efficacy of anti-TNF therapies in CD. METHODS After screening 506 studies, reviewers extracted information on 10 studies. Traditional meta-analysis (TMA) was used to c...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- ACP journal club
دوره 148 4 شماره
صفحات -
تاریخ انتشار 2008